Covid-19 Impact on Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market, Global Research Reports 2020-2021
This report covers market size and forecasts of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics, including the following market information:
Major competitors identified in this market include Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, etc.
Based on the Region:
- Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
- Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
- Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
- Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Major competitors identified in this market include Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, etc.
Based on the Region:
- Asia-Pacific (China, Japan, South Korea, India and ASEAN)
- North America (US and Canada)
- Europe (Germany, France, UK and Italy)
- Rest of World (Latin America, Middle East & Africa)
- Oral Therapy
- Injectable Therapy
- Hospitals & Clinics
- Home Settings
- Ambulatory Surgical Centers (ASCs)
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Industry
1.7 COVID-19 Impact: Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Trends
2 GLOBAL CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS QUARTERLY MARKET SIZE ANALYSIS
2.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business Impact Assessment - COVID-19
2.1.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 QUARTERLY COMPETITIVE ASSESSMENT, 2020
3.1 By Players, Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Market Size, 2019 VS 2020
3.2 By Players, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Headquarters and Area Served
3.3 Date of Key Players Enter into Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market
3.4 Key Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 IMPACT OF COVID-19 ON CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS SEGMENTS, BY TYPE
4.1 Introduction
1.4.1 Oral Therapy
1.4.2 Injectable Therapy
4.2 By Type, Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021
5 IMPACT OF COVID-19 ON CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS SEGMENTS, BY APPLICATION
5.1 Overview
5.5.1 Hospitals & Clinics
5.5.2 Home Settings
5.5.3 Ambulatory Surgical Centers (ASCs)
5.2 By Application, Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021
5.2.1 By Application, Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application, 2019-2021
6 GEOGRAPHIC ANALYSIS
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 COMPANY PROFILES
7.1 Astellas Inc.
7.1.1 Astellas Inc. Business Overview
7.1.2 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Revenue, 2020
7.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Introduction
7.1.4 Astellas Inc. Response to COVID-19 and Related Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Business Overview
7.2.2 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Revenue, 2020
7.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Introduction
7.2.4 Johnson & Johnson Response to COVID-19 and Related Developments
7.3 Sanofi S.A
7.3.1 Sanofi S.A Business Overview
7.3.2 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Revenue, 2020
7.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Introduction
7.3.4 Sanofi S.A Response to COVID-19 and Related Developments
7.4 Dendreon Corporation
7.4.1 Dendreon Corporation Business Overview
7.4.2 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Revenue, 2020
7.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Introduction
7.4.4 Dendreon Corporation Response to COVID-19 and Related Developments
7.5 Bayer AG
7.5.1 Bayer AG Business Overview
7.5.2 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Revenue, 2020
7.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Introduction
7.5.4 Bayer AG Response to COVID-19 and Related Developments
8 KEY FINDINGS
9 APPENDIX
9.1 About US
9.2 Disclaimer
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Industry
1.7 COVID-19 Impact: Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Trends
2 GLOBAL CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS QUARTERLY MARKET SIZE ANALYSIS
2.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business Impact Assessment - COVID-19
2.1.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 QUARTERLY COMPETITIVE ASSESSMENT, 2020
3.1 By Players, Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Market Size, 2019 VS 2020
3.2 By Players, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Headquarters and Area Served
3.3 Date of Key Players Enter into Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market
3.4 Key Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 IMPACT OF COVID-19 ON CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS SEGMENTS, BY TYPE
4.1 Introduction
1.4.1 Oral Therapy
1.4.2 Injectable Therapy
4.2 By Type, Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021
5 IMPACT OF COVID-19 ON CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS SEGMENTS, BY APPLICATION
5.1 Overview
5.5.1 Hospitals & Clinics
5.5.2 Home Settings
5.5.3 Ambulatory Surgical Centers (ASCs)
5.2 By Application, Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021
5.2.1 By Application, Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application, 2019-2021
6 GEOGRAPHIC ANALYSIS
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 COMPANY PROFILES
7.1 Astellas Inc.
7.1.1 Astellas Inc. Business Overview
7.1.2 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Revenue, 2020
7.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Introduction
7.1.4 Astellas Inc. Response to COVID-19 and Related Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Business Overview
7.2.2 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Revenue, 2020
7.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Introduction
7.2.4 Johnson & Johnson Response to COVID-19 and Related Developments
7.3 Sanofi S.A
7.3.1 Sanofi S.A Business Overview
7.3.2 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Revenue, 2020
7.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Introduction
7.3.4 Sanofi S.A Response to COVID-19 and Related Developments
7.4 Dendreon Corporation
7.4.1 Dendreon Corporation Business Overview
7.4.2 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Revenue, 2020
7.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Introduction
7.4.4 Dendreon Corporation Response to COVID-19 and Related Developments
7.5 Bayer AG
7.5.1 Bayer AG Business Overview
7.5.2 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Revenue, 2020
7.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Introduction
7.5.4 Bayer AG Response to COVID-19 and Related Developments
8 KEY FINDINGS
9 APPENDIX
9.1 About US
9.2 Disclaimer
LIST OF TABLES
Table 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Assessment
Table 9. COVID-19 Impact: Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Trends
Table 10. COVID-19 Impact Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size
Table 11. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Market Size, 2020 (US$ Million)
Table 12. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 13. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Growth Drivers
Table 14. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Restraints
Table 15. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Opportunities
Table 16. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Challenges
Table 17. By Players, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 18. Key Players, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2019 VS 2020 (%)
Table 19. Key Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players Headquarters and Area Served
Table 20. Date of Key Players Enter into Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market
Table 21. Key Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Type
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. By Players, Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2019-2021, (US$ Million)
Table 24. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application: 2019-2021 (US$ Million)
Table 25. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region, 2019-2021 (US$ Million)
Table 26. By Country, North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 27. By Type, US Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 28. By Application, US Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 29. By Type, Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 30. By Application, Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 31. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 32. By Country, Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 33. By Type, Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 34. By Application, Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 35. By Type, France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 36. By Application, France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 37. By Type, UK Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 38. By Application, UK Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 39. By Type, Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 40. By Application, Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 41. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 42. By Region, Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 43. By Type, China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 44. By Application, China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 45. By Type, Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 46. By Application, Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 47. By Type, South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 48. By Application, South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 49. By Type, India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 50. By Application, India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 51. By Type, ASEAN Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 52. By Application, ASEAN Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 53. By Type, Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 54. By Application, Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 55. By Type, Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 56. By Application, Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 57. Astellas Inc. Business Overview
Table 58. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 60. Astellas Inc. Response to COVID-19 and Related Developments
Table 61. Johnson & Johnson Business Overview
Table 62. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 64. Johnson & Johnson Response to COVID-19 and Related Developments
Table 65. Sanofi S.A Business Overview
Table 66. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 68. Sanofi S.A Response to COVID-19 and Related Developments
Table 69. Dendreon Corporation Business Overview
Table 70. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 72. Dendreon Corporation Response to COVID-19 and Related Developments
Table 73. Bayer AG Business Overview
Table 74. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 76. Bayer AG Response to COVID-19 and Related Developments
Table 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Assessment
Table 9. COVID-19 Impact: Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Trends
Table 10. COVID-19 Impact Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size
Table 11. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Market Size, 2020 (US$ Million)
Table 12. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 13. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Growth Drivers
Table 14. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Restraints
Table 15. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Opportunities
Table 16. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Challenges
Table 17. By Players, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 18. Key Players, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2019 VS 2020 (%)
Table 19. Key Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players Headquarters and Area Served
Table 20. Date of Key Players Enter into Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market
Table 21. Key Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Type
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. By Players, Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2019-2021, (US$ Million)
Table 24. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application: 2019-2021 (US$ Million)
Table 25. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region, 2019-2021 (US$ Million)
Table 26. By Country, North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 27. By Type, US Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 28. By Application, US Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 29. By Type, Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 30. By Application, Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 31. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 32. By Country, Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 33. By Type, Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 34. By Application, Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 35. By Type, France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 36. By Application, France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 37. By Type, UK Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 38. By Application, UK Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 39. By Type, Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 40. By Application, Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 41. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 42. By Region, Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 43. By Type, China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 44. By Application, China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 45. By Type, Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 46. By Application, Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 47. By Type, South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 48. By Application, South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 49. By Type, India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 50. By Application, India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 51. By Type, ASEAN Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 52. By Application, ASEAN Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 53. By Type, Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 54. By Application, Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 55. By Type, Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 56. By Application, Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021 (US$ Million)
Table 57. Astellas Inc. Business Overview
Table 58. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 60. Astellas Inc. Response to COVID-19 and Related Developments
Table 61. Johnson & Johnson Business Overview
Table 62. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 64. Johnson & Johnson Response to COVID-19 and Related Developments
Table 65. Sanofi S.A Business Overview
Table 66. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 68. Sanofi S.A Response to COVID-19 and Related Developments
Table 69. Dendreon Corporation Business Overview
Table 70. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 72. Dendreon Corporation Response to COVID-19 and Related Developments
Table 73. Bayer AG Business Overview
Table 74. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 76. Bayer AG Response to COVID-19 and Related Developments
LIST OF FIGURES
Figure 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Picture
Figure 2. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share, 2019-2021
Figure 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Picture
Figure 2. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share, 2019-2021
